Yumeng Mao

JSON
CSV
XLSX
TXT

SciLifeLab Fellow since 2019.

Primary: Shown in the list of current labels.

Year 2023

PubMed DOI Crossref
Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice.
O' Donovan DH, Baker D, Ciotta G, ..., Tang H, Valge-Archer V
Bioorg. Med. Chem. Lett. 96 (-) 129518 [2023-10-12; online 2023-10-12]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
IL-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy.
Tunalı G, Rúbies Bedós M, Nagarajan D, ..., Papakyriacou I, Mao Y
J. Clin. Invest. 133 (7) - [2023-04-03; online 2023-04-03]
SciLifeLab Fellow Yumeng Mao

Year 2021

PubMed DOI Crossref
Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.
McCoull W, Boyd S, Brown MR, ..., Zhu Q, Smith PD
J Med Chem 64 (18) 13524-13539 [2021-09-23; online 2021-09-03]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy.
Wennerberg E, Lundqvist A, Mao Y, Mougiakakos D
Front Immunol 12 (-) 718844 [2021-07-01; online 2021-07-01]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.
Van Wigcheren GF, De Haas N, Mulder TA, ..., Hato SV, De Vries IJM
Oncoimmunology 10 (1) 1935557 [2021-06-27; online 2021-06-27]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells.
Chen Z, Yang Y, Neo SY, ..., Sarhan D, Lundqvist A
EMBO Rep. 22 (3) e51329 [2021-03-03; online 2021-01-22]
SciLifeLab Fellow Yumeng Mao

Year 2020

PubMed DOI Crossref
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
Degorce SL, Tavana O, Banks E, ..., Yang B, Edmondson SD
J Med Chem 63 (18) 10460-10473 [2020-09-24; online 2020-09-14]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.
Natoli M, Bonito N, Robinson JD, Ghaem-Maghami S, Mao Y
Cancer Immunol. Immunother. 69 (8) 1391-1401 [2020-08-00; online 2020-03-21]
SciLifeLab Fellow Yumeng Mao

Year 2019

PubMed DOI Crossref
What industry can teach academia.
Mao Y
Science (New York, N.Y.) 365 (6459) 1342 [2019-09-20; online 2019-10-12]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy.
O' Donovan DH, Mao Y, Mele DA
Current medicinal chemistry 27 (34) 5654-5674 [2019-06-30; online 2019-06-30]
SciLifeLab Fellow Yumeng Mao

Year 2016

PubMed DOI Crossref
IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.
Mao Y, van Hoef V, Zhang X, ..., Kiessling R, Lundqvist A
Blood 128 (11) 1475-1489 [2016-09-15; online 2016-07-27]
Affiliated researcher SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.
Eissler N, Mao Y, Brodin D, ..., Kiessling R, Kogner P
Oncoimmunology 5 (12) e1232222 [2016-09-09; online 2016-09-09]
Affiliated researcher SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
Mao Y, Eissler N, Blanc KL, ..., Kogner P, Kiessling R
Clin. Cancer Res. 22 (15) 3849-3859 [2016-08-01; online 2016-03-08]
SciLifeLab Fellow Yumeng Mao

Year 2015

PubMed DOI Crossref
Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.
Sarhan D, Palma M, Mao Y, ..., Österborg A, Lundqvist A
Eur. J. Immunol. 45 (6) 1783-1793 [2015-06-00; online 2015-04-17]
SciLifeLab Fellow Yumeng Mao

Year 2014

PubMed DOI Crossref
Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
Mao Y, Sarhan D, Steven A, ..., Kiessling R, Lundqvist A
Clin. Cancer Res. 20 (15) 4096-4106 [2014-08-01; online 2014-06-06]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.
Mao Y, Poschke I, Kiessling R
J. Intern. Med. 276 (2) 154-170 [2014-08-00; online 2014-03-24]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells.
Kiessling R, Mao Y, Pico de Coaña Y
Clin. Cancer Res. 20 (6) 1401-1403 [2014-03-15; online 2014-02-13]
SciLifeLab Fellow Yumeng Mao

Year 2013

PubMed DOI Crossref
Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes.
Poschke I, Mao Y, Kiessling R, de Boniface J
J Transl Med 11 (-) 290 [2013-11-16; online 2013-11-16]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.
Pico de Coaña Y, Poschke I, Gentilcore G, ..., Masucci GV, Kiessling R
Cancer Immunol Res 1 (3) 158-162 [2013-09-00; online 2013-08-02]
SciLifeLab Fellow Yumeng Mao
DOI Crossref
Cyclooxygenase-2
Mao Y, Poschke I, Kiessling R
Oncoimmunology 2 (8) e25157 [2013-08-00; online 2014-10-27]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.
Mao Y, Poschke I, Wennerberg E, ..., Lundqvist A, Kiessling R
Cancer Res. 73 (13) 3877-3887 [2013-07-01; online 2013-04-30]
SciLifeLab Fellow Yumeng Mao

Year 2012

PubMed DOI Crossref
Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients.
de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I
Oncoimmunology 1 (8) 1305-1312 [2012-11-01; online 2012-12-18]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients.
Poschke I, De Boniface J, Mao Y, Kiessling R
Int. J. Cancer 131 (7) 1611-1620 [2012-10-01; online 2012-01-31]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells.
Kiessling R, Okita R, Mougiakakos D, ..., Mimura K, Kono K
Oncoimmunology 1 (7) 1200-1201 [2012-10-01; online 2012-11-22]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function.
Boniface JD, Poschke I, Mao Y, Kiessling R
Int. J. Cancer 131 (1) 129-139 [2012-07-01; online 2011-08-30]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.
Poschke I, Mao Y, Adamson L, ..., Masucci G, Kiessling R
Cancer Immunol. Immunother. 61 (6) 827-838 [2012-06-00; online 2011-11-12]
SciLifeLab Fellow Yumeng Mao
PubMed DOI Crossref
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
Okita R, Mougiakakos D, Ando T, ..., Mimura K, Kiessling R
J. Immunol. 188 (5) 2136-2145 [2012-03-01; online 2012-02-01]
SciLifeLab Fellow Yumeng Mao

Year 2010

PubMed DOI Crossref
Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy.
Lei C, Liu P, Chen B, ..., Liu J, Hellstrom KE
Journal of the American Chemical Society 132 (20) 6906-6907 [2010-05-26; online 2010-05-04]
SciLifeLab Fellow Yumeng Mao
SciLifeLab Data Centre
Publications 9.5.0